What is the MCL global Prognostic Index (MIPI)?

1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. 1999 Dec. 10(12):1419-32. [Medline].

2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1. 84(5):1361-92. [Medline].

3. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non- Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982 May 15. 49(10):2112-35. [Medline].

4. American Cancer Society. Cancer Facts & Figures 2019. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed: March 11, 2019.

5. Gao J, Peterson L, Nelson B, Goolsby C, Chen YH. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009 Nov. 132(5):699-706. [Medline].

6. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma. 2009 Dec. 50(12):1937-50. [Medline].

7. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol. 2010 Jan. 23(1):105-12. [Medline].

8. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell Lymphomas, Version 2.2019. NCCN. Available at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. March 6, 2019; Accessed: March 13, 2019.

9. Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015 Feb. 29 (2):464-73. [Medline].

10. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015 Jul 24. [Medline].

11. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med. 2015 Nov 5. 373 (19):1835-44. [Medline]. [Full Text].

12. Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011 Nov 3. 118(18):4808-16. [Medline]. [Full Text].

13. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000 Jan. 18(2):317-24. [Medline].

14. Mulcahy N. FDA Approves Bortezomib (Velcade) for Untreated MCL. Medscape Medical News. Available at http://www.medscape.com/viewarticle/833054. October 9, 2014; Accessed: November 4, 2017.

15. Kasamon YL, Jones RJ, Brodsky RA, et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2009 Oct 30. epub ahead of print. [Medline].

16. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001 Sep-Oct. 42(5):1015-22. [Medline].

17. Hiddemann W, Dreyling M, Unterhalt M, et al. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol. 2003 Feb. 30(1 Suppl 2):16-20. [Medline].

18. Smith SD, Gandhy S, Gopal AK, Reddy P, Shadman M, Till BG, et al. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Jan. 19 (1):48-52. [Medline].

19. Goy A, Younes A, McLaughlin P, et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004. 22 (July 15 suppl):14S (6581).

20. O'Connor OA. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004. 22 (July 15 suppl):14S (6582).

21. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct 20. 24(30):4867-74. [Medline].

22. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May. 12(5):431-40. [Medline].

23. FDA Approves Lenalidomide. US Food and Drug Administration. Available at https://wayback.archive-it.org/7993/20161022171115/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm. Accessed: November 4, 2017.

24. Morabito F, Skafi M, Recchia AG, Kashkeesh A, Hindiyeh M, Sabatleen A, et al. Lenalidomide for the treatment of mantle cell lymphoma. Expert Opin Pharmacother. 2019 Jan 4. 1-8. [Medline].

25. Wang ML, Rule S, Martin P, Goy A, Auer R, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8. 369 (6):507-16. [Medline]. [Full Text].

26. Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Jan 28. [Medline].

27. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017 Dec 11. [Medline].

28. Cheung MC, Maceachern JA, Haynes AE, Meyer RM, Imrie K, Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. I-Tositumomab in lymphoma. Curr Oncol. 2009 Sep. 16 (5):32-47. [Medline]. [Full Text].

29. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 1. 27(31):5213-8. [Medline].

30. Borgerding A, Hasenkamp J, Glass B, Wulf G, Trumper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol. 2010 Mar. 89(3):283-9. [Medline]. [Full Text].

31. Kaufmann H, Raderer M, Wöhrer S. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004 Oct 15. 104(8):2269-71. [Medline].

32. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan. 16(1):13-8. [Medline].

33. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer. 2003 Dec 15. 98(12):2630-5. [Medline].

34. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon, France: International Agency for Research on Cancer; 2017.

35. [Guideline] Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1. 28 (suppl_4):iv62-iv71. [Medline]. [Full Text].

36. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15. 111 (2):558-65. [Medline]. [Full Text].

37. Agazzi A. Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014. Ecancermedicalscience. 2015. 9:514. [Medline]. [Full Text].

38. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma. 2009 Dec. 50(12):1916-30. [Medline].

39. Bogner C, Dechow T, Ringshausen I, et al. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol. 2010 Jan. 148(1):99-109. [Medline].

40. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, et al. Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. J Clin Oncol. 2011 Mar 20. 29(9):1198-203. [Medline].

41. Lowes R. FDA OKs Ibrutinib (Imbruvica) for Mantle Cell Lymphoma. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/814307. November 13, 2013; Accessed: November 4, 2017.

42. U.S. Food and Drug Administration. FDA approves Imbruvica for rare blood cancer. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374761.htm#. Accessed: November 18, 2013.

43. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016 Sep 2. 9 (1):80. [Medline]. [Full Text].

Muhammad Rashid Abbasi, MD Former Assistant Professor of Medicine, Albert Einstein College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Hematology/Oncology, Jacobi Medical Center, Morristown Memorial Hospital, and St Clare's Hospital

Muhammad Rashid Abbasi, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Hematology

Disclosure: Nothing to disclose.

Joseph A Sparano, MD Professor, Department of Medicine (Oncology), Professor, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine; Associate Chairman for Clinical Research, Department of Oncology, Montefiore Medical Center; Associate Director for Clinical Research, Albert Einstein Cancer Center

Joseph A Sparano, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.